University of Florida
University of Florida

Tag: OxThera AB

Phase 3 ePHex Study: OxThera Reports Results

Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.

New OxThera/Oxabact US Patent Granted

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.

Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.

OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational bi-modal enteric biotherapy containing a lyophilized formulation of Oxalobacter formigenes for the treatment of adults and children with primary […]

OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter Formigenes

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that, based on a positive opinion from the Paediatric Committee (PDCO), the European Medicines Agency (EMA) has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria. “We are pleased to […]

Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study with Oxabact in Primary Hyperoxaluria

UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria (PH), announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH. OC5-OL-01 is the longest efficacy and safety study of any intervention to lower the oxalate burden […]

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria, announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to treat patients in […]

OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD (PR Newswire)

UF startup OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego. “We are pleased to present […]